Summary: In a 7-month crossover trial in adults with type 2 diabetes, a dietary phytomix (Dibifree) added to usual treatment significantly reduced HbA1c and fasting and postprandial glucose versus placebo, with effects sustained after washout and a fall in body fat.
PICO Summary
| Element | Detail |
|---|---|
| Population | 40 adults with type 2 diabetes; 7-month randomised, double-blind, placebo-controlled crossover trial, Taiwan (biotech-affiliated). |
| Intervention | Dibifree dietary phytomix 15 g/day as add-on therapy, for two 3-month sessions separated by a 1-month washout. |
| Comparison | Placebo, with placebo recipients switched to Dibifree in the second session. |
| Outcome | Dibifree significantly reduced HbA1c and fasting and postprandial glucose versus placebo, with sustained effects after washout and re-challenge, and body-fat percentage also fell. Mechanistic work showed enhanced GLP-1 secretion, DPP-4 and α-glucosidase inhibition, reduced advanced glycation, suppressed adipogenesis, and M2 macrophage polarisation. |
Expert Commentary
This is a mechanistically thorough study pairing a clinical crossover with extensive laboratory work, and the design has real strengths, since the crossover with washout and re-challenge, where benefit reappeared on re-exposure, is a more convincing demonstration of a genuine effect than a single parallel comparison. The glycaemic signal is meaningful, with reductions in HbA1c and both fasting and postprandial glucose plus a fall in body fat, and the proposed multi-target mechanism, spanning incretin enhancement, enzyme inhibition, reduced glycation, and immune modulation, is biologically coherent if necessarily exploratory. The caveat that must travel prominently is provenance and scale: this is a small trial of 40 patients conducted with biotechnology-company involvement in developing the product, which is a recognised source of bias in functional-food research and calls for independent replication. The complex formulation also makes it hard to attribute the effect to any single component, and longer, larger, independent trials are needed. Can I use this with my patients? Cautiously and as an adjunct, if at all. For a patient on proven therapy interested in a dietary add-on, the crossover evidence is more persuasive than most supplement studies, but I would be candid about the small size and industry involvement and would not let it substitute for established glucose-lowering treatment.
References
Huang TY, Dai NT, Liao HJ, et al. Dibifree, a dietary phytomix, improves glycemic control and adiposity via modulation of the gut-pancreas-adipose-immune axis in type 2 diabetes. Food Res Int. 2025;223(Pt 1):117820. doi:10.1016/j.foodres.2025.117820